Clinical Trials Sponsored by NoNO Inc.

Total 37391 results

Novo Nordisk A/S

Completed

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

Congenital Bleeding Disorder | Haemophilia B | Haemostasis

United States
Novo Nordisk A/S

Completed

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations in Healthy Volunteers

Healthy | Diabetes

United States
Novo Nordisk A/S

Completed

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Healthy | Diabetes

United States
Novo Nordisk A/S

Completed

An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Diabetes Mellitus, Type 2 | Diabetes

Spain, Germany, France, United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of Long-term Somatropin Treatment in Adults (NordiWIN)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

South Africa, United Arab Emirates, India
Novo Nordisk A/S

Completed

A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Brazil
Novo Nordisk A/S

Completed

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

Healthy | Growth Disorder

United States
Novo Nordisk A/S

Completed

Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

Spain
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Sweden, Denmark
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months

Menopause | Postmenopausal Bleeding

Sweden, Norway
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Congenital Bleeding Disorder | Congenital FVII Deficiency

Japan
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Observational Study on Levemir® in Obese Diabetic Patients (KILOS)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Netherlands, Slovenia
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes (IDEALS)

Diabetes Mellitus, Type 2 | Diabetes

Algeria
Novo Nordisk A/S

Completed

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

Chronic Kidney Disease | Turner Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Genetic Disorder | Delivery Systems | Foetal Growth Problem | Small for Gestational Age

France
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes (INTENSIV)

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia (ACQUI-7)

Acquired Bleeding Disorder | Acquired Haemophilia

France
Novo Nordisk A/S

Completed

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Terminated

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Two Identical NN1250 Formulations in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Novo Nordisk A/S

Completed

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Not yet recruiting

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

Healthy Volunteers Sickle Cell Disease, Thalassemia

United States
Novo Nordisk A/S

Not yet recruiting

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Obesity

United Kingdom, Germany, Canada, United States, France
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Novo Nordisk A/S

Not yet recruiting

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Type 2 Diabetes
Novo Nordisk A/S

Recruiting

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Obesity | Overweight

Germany
Novo Nordisk A/S

Recruiting

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Obesity

Germany
Novo Nordisk A/S

Recruiting

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Healthy Volunteers - Liver Diseases

United Kingdom
Novo Nordisk A/S

Recruiting

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Growth Hormone Deficiency in Children

Japan
Novo Nordisk A/S

Recruiting

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Obesity | Overweight

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6)

Obesity or Overweight

China
Novo Nordisk A/S

Recruiting

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (OASIS 3)

Obesity | Overweight

China
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Obesity or Overweight

Taiwan, Japan
Novo Nordisk A/S

Not yet recruiting

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2

3

Subscribe